

CYTOCHROMES SIMPLIFIED: AN INTRODUCTION TO GENETIC INFLUENCES ON DRUG METABOLISM

Timothy Dellenbaugh, M.D.

Residency Director

Associate Professor of Psychiatry

University of Missouri-Kansas City

Assistant Medical Director

Center for Behavioral Medicine

At the conclusion of the activity, the participant will be able to:

1. discuss genetic influences on psychiatric drug metabolism through Cytochrome P450 2D6
2. summarize genetic causes and clinical implications of 2D6 phenotypes: ultra-rapid, extensive, intermediate, and poor
3. develop strategies for learning cytochrome-based drug interactions

Important but not covered

- Receptor variations (Pharmacodynamics)
 - ▣ D2, D4, 5HT_{2α}, etc
- Reuptake pumps
 - ▣ DA, 5HT
- ABC transporters

Definitions

- Substrate
- Inhibitor
- Inducer

Smokers need higher than typical doses of most antipsychotics

- T/F

How quickly does starting an Inhibitor cause change in metabolism?

- A. Depends on $\frac{1}{2}$ life of substrate
- B. Depends on $\frac{1}{2}$ life of inhibitor
- C. Depends on $\frac{1}{2}$ life of cytochrome
- D. Depends on rate of cytochrome production

How quickly does stopping an Inhibitor cause change in metabolism?

- A. Depends on $\frac{1}{2}$ life of substrate
- B. Depends on $\frac{1}{2}$ life of inhibitor
- C. Depends on $\frac{1}{2}$ life of cytochrome
- D. Depends on rate of cytochrome production

A potent inhibitor decreases cyp 2D6 activity for which groups?

- A. ultra-rapid
- B. extensive
- C. intermediate
- D. poor
- E. all groups would decrease

How quickly does stopping an inducer cause change in metabolism?

- A. Depends on $\frac{1}{2}$ life of substrate
- B. Depends on $\frac{1}{2}$ life of inhibitor
- C. Depends on $\frac{1}{2}$ life of cytochrome
- D. Depends on rate of cytochrome production

How many genetic variants of 2D6 have been identified?

A. 5-10

B. 10-25

C. 25-50

D. 50-100

E. >100

What is Cytochrome P450 2D6 *1


- Cytochrome
 - What does it do?
 - Why named P450?
 - Superfamily
- Family- >40% AA identity
 - CYP1, CYP2
- Subfamily- >55% A,B,C,D
- Individual Loci- 1,2,3
- Alleles- >97%- *1, *2, *41

Total cyp 2D6 activity depends on which of the following?


- Which dominant allele is inherited
- Which pair of alleles are inherited

- How much 2D6 is produced
- Which variations of 2D6 are produced

Drug-Metabolizing Enzymes




Phase I: modification of functional groups





Phase II: conjugation with endogenous substituents

Most DME have clinically relevant polymorphisms
Those with changes in drug effects are separated from pie.

Enzyme synthesis



2D6



CYP2D6

- highly polymorphic gene
- >130 genetic variations described
- Duplication
- Deletion
- Splice defect
- SNP


ANESTHESIOLOGY



The Journal of the American Society of Anesthesiologists, Inc.

From: Genetic Variation, β -blockers, and Perioperative Myocardial Infarction

Anesthesiology. 2011;115(6):1316-1327. doi:10.1097/ALN.0b013e3182315eb2



Inducers

Promote

	1A2	2B6	2C8	2C9	2C19	2D6	2E1	3A4/5		1A2	2B6	2C8	2C9	2C19	2D6	2E1	3A4/5		1A2	2B6	2C8	2C9	2C19	2D6	2E1	3A4/5	
bosentan									isoniazid										oxcarbazepine								
carbamazepine	■								lansoprazole	■									phenobarbital								
cyclophosphamide									vegetables (cabbage, broccoli)	■									phenytoin								
dexamethasone				■					meprobamate										primidone								
efavirenz		■							metamizole		■								rifabutin								
ethanol									St John's wort										rifampicin	■							
etravirine									modafinil	■	■								ritonavir								
felbamate									nevirapine										tobacco (tar)								
ifosfamide									omeprazole	■									topiramate								

■ potent inducer ■ weak inducer

Table 3. Inducers of cytochromes P450

Inhibition

The impact depends on: a) relative importance of the inhibited elimination pathway, relative to the total clearance; b) whether active metabolites are present or not, and c) concentration of the inhibitor. Upon cessation of the inhibitor treatment CYP returns to its normal activity after elimination of the inhibitor (4 half-lives). *Examples* : CYP2C9 's activity is strongly inhibited by **amiodarone**. In association with **acenocoumarol**, a CYP2C9 substrate, amiodarone will slow the latter's elimination, potentially causing haemorrhages, which justify adapting the posology and closely monitoring the INR. **Fluoxetine** inhibits strongly the activity of CYP2D6. In association with **codeine**, it can abolish any efficacy of the latter.

Induction

The impact depends upon: a) relative importance of the induced elimination pathway relative to the total clearance, b) whether active metabolites are present or not, and c) concentration of the inducer. Upon cessation of the inducer treatment CYP progressively returns to its normal activity (> 2 weeks after elimination of the inhibitor from blood). *Example*: St John's Wort progressively and potently induces CYP3A4 activity. St John's Wort strongly accelerates the elimination of ethinylestradiol, a major CYP3A4 substrate, which means that contraception will not be ensured and other contraceptive means will be needed.

How to learn

- Daily use vs. episodic use
- Focus on clinical relevance
- Ignore small effects
- Organize data for visual recall
- Selective sources

Metabolic Pathways	1A2	3A4	2D6
Psychiatric Substrates			
Other Important Substrates			
Inhibitors			
Inducers			
Genetics			

Where can you find reliable and useful drug interaction data?

- <http://medicine.iupui.edu/clinpharm/ddis/main-table/>
- <http://www.fda.gov/>
- <https://www.pharmgkb.org/index.jsp>

Smokers need higher than typical doses of most antipsychotics

□ T/F

How quickly does starting an Inhibitor cause change in metabolism?

- A. Depends on $\frac{1}{2}$ life of substrate
- B. Depends on $\frac{1}{2}$ life of inhibitor**
- C. Depends on $\frac{1}{2}$ life of cytochrome
- D. Depends on rate of cytochrome production

How quickly does stopping an Inhibitor cause change in metabolism?

- A. Depends on $\frac{1}{2}$ life of substrate
- B. Depends on $\frac{1}{2}$ life of inhibitor**
- C. Depends on $\frac{1}{2}$ life of cytochrome
- D. Depends on rate of cytochrome production

A potent inhibitor decreases cyp 2D6 activity for which groups?

- A. ultra-rapid-yes
- B. extensive-yes
- C. intermediate-yes
- D. poor-no,
it's already broken

How quickly does stopping an inducer cause change in metabolism?

- A. Depends on $\frac{1}{2}$ life of substrate
- B. Depends on $\frac{1}{2}$ life of inhibitor
- C. Depends on $\frac{1}{2}$ life of cytochrome**
- D. Depends on rate of cytochrome production**

How many genetic variants of 2D6 have been identified?

A. 5-10

B. 10-25

C. 25-50

D. 50-100

E. >100

References

- "Crystal Structure of Human Cytochrome P450 2D6." *Crystal Structure of Human Cytochrome P450 2D6*. The European Synchrotron. Web. 13 May 2016. <<http://www.esrf.eu/UsersAndScience/Publications/Highlights/2006/SB/SB09>>.
- Ingelman-Sundberg, M. "Genetic Polymorphisms of Cytochrome P450 2D6 (CYP2D6): Clinical Consequences, Evolutionary Aspects and Functional Diversity." *Pharmacogenomics J The Pharmacogenomics Journal* 5.1 (2004): 6-13. Web.
- M. Whirl-Carrillo, E.M. McDonagh, J. M. Hebert, L. Gong, K. Sangkuhl, C.F. Thorn, R.B. Altman and T.E. Klein. "[Pharmacogenomics Knowledge for Personalized Medicine](#)" *Clinical Pharmacology & Therapeutics* (2012) 92(4): 414-417
- Mrazek, David. *Psychiatric Pharmacogenomics*. New York: Oxford UP, 2010. Print.
- *P450 Drug Interaction Table*. Indiana University. Web. 13 May 2016. <<http://medicine.iupui.edu/clinpharm/ddis/main-table/>>.
- *protein: protein production*. Art. *Britannica Online for Kids*. Web. 21 May 2016. <<http://kids.britannica.com/elementary/art-114928>>.
- Sim, Sarah C. "CYP2D6 Allele Nomenclature." *CYP2D6 Allele Nomenclature*. 19 Jan. 2016. Web. 13 May 2016. <<http://www.cypalleles.ki.se/cyp2d6.htm>>.
- Yamazaki, Hiroshi. *Fifty Years of Cytochrome P450 Research*. Print.
- Samer, C. F., K. Ing Lorenzini, V. Rollason, Y. Daali, and J. A. Desmeules. "Applications of CYP450 Testing in the Clinical Setting." *Mol Diagn Ther Molecular Diagnosis & Therapy* 17.3 (2013): 165-84.